Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology...

Full description

Bibliographic Details
Main Authors:	Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2021-05-01
Series:	Современная онкология
Subjects:	hr+/her2- metastatic breast cancer cdk4/6 combined endocrine therapy with cdk4/6 inhibitors hormone resistance eribulin eribulin chemotherapy efficacy eribulin chemotherapy safety visceral metastases lung metastases
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/70308/51242

Similar Items

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
by: Irina V Kolyadina, et al.
Published: (2019-06-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Vaginal metastasis from breast cancer: A case report
by: Yan Yunbo, et al.
Published: (2023-06-01)

Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen
by: Sugandha Bhatia, et al.
Published: (2020-04-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
by: Eijiro Shimada, et al.
Published: (2021-10-01)

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
by: Yasuhiro Fujisawa, et al.
Published: (2018-03-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study
by: Shigemasa Takamizawa, et al.
Published: (2022-01-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
by: Milana Bergamino Sirvén, et al.
Published: (2019-11-01)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
by: Ana López González, et al.
Published: (2022-11-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
by: Søren Brøgger Christensen
Published: (2022-09-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01)

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
by: Nicla La Verde, et al.
Published: (2022-10-01)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
by: María López-Álvarez, et al.
Published: (2022-12-01)

Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE)
by: Pallavi Sachdev, et al.
Published: (2022-09-01)

Long-term survival with eribulin monotherapy after whole brain radiation therapy in a patient with brain metastasis from breast cancer
by: Sung Ui Jung, et al.
Published: (2020-10-01)

B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study
by: Liubov A. Tashireva, et al.
Published: (2022-06-01)

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms
by: Hugo Passos Vicari, et al.
Published: (2022-12-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
by: Alessandro De Vita, et al.
Published: (2016-12-01)

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
by: Matteo Paccagnella, et al.
Published: (2022-01-01)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
by: Yeong Gyu Jeong, et al.
Published: (2023-10-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

Multifarious targets beyond microtubules—role of eribulin in cancer therapy
by: Priya Seshadri, et al.
Published: (2021-12-01)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
by: Anne-Claire Hardy-Bessard, et al.
Published: (2020-12-01)